A Multi-Centre, Open-Label, Randomised Trial Evaluating Two Subcutaneous Injection Techniques and Intramuscular Administration of Degarelix in Patients With Prostate Cancer

Trial Profile

A Multi-Centre, Open-Label, Randomised Trial Evaluating Two Subcutaneous Injection Techniques and Intramuscular Administration of Degarelix in Patients With Prostate Cancer

Completed
Phase of Trial: Phase III

Latest Information Update: 04 Sep 2017

At a glance

  • Drugs Degarelix (Primary)
  • Indications Prostate cancer
  • Focus Adverse reactions; Registrational
  • Sponsors Ferring Pharmaceuticals
  • Most Recent Events

    • 03 Jul 2017 Status changed from active, no longer recruiting to completed.
    • 07 Dec 2016 Status changed from recruiting to active, no longer recruiting.
    • 11 Dec 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top